PDF(Pubmed)
Abstract：
OBJECTIVE: The aim of the study was to evaluate the baseline data of women with breast cancer (BC) undergoing treatment in an intercontinental comparison.
METHODS: This study included 99,571 women with BC from Europe (70,834), Asia (18,208), and Latin America (10,529) enrolled between 2017 and 2021, based on data from IQVIA\'s Oncology Dynamics database. This source is supplied with information by means of a cross-sectional partially retrospective survey collecting anonymized data on inpatients and outpatients treated by a representative panel of oncologists. A multivariable logistic regression model was used to investigate the probability of metastases.
RESULTS: The data available in Asia (98%) and Latin America (100%) were hospital data, while in Europe, patients were treated both in hospitals and in office-based practices (62%, 38%). The mean age in Asia and Latin America (57 ± 13) was lower than in Europe (61 ± 13; p < 0.001). Lobular BC was diagnosed twice as often in Europe compared to Asia and Latin America (15.2%, 9.8%, 8.0%). The number of patients with metastasized hormone receptor-positive (HR +) BC was significantly higher in Europe and Latin America than in Asia (76%, 68%; p < 0.001). The highest number of women with metastasized BC was reported in Europe (26% compared to 14% and 20%, respectively, in Asia and Latin America). Across the continents, the percentage of women with BC who experienced metastases was 51-61% for bone, 30-39% for lung and 25-32% for liver, followed by 3-6% for skin and 3% for brain.
CONCLUSIONS: Women with BC treated in Europe tend to be significantly older and more likely to develop metastases than women in Asia and Latin America, except for lung metastases.
METHODS: This study included 99,571 women with BC from Europe (70,834), Asia (18,208), and Latin America (10,529) enrolled between 2017 and 2021, based on data from IQVIA\'s Oncology Dynamics database. This source is supplied with information by means of a cross-sectional partially retrospective survey collecting anonymized data on inpatients and outpatients treated by a representative panel of oncologists. A multivariable logistic regression model was used to investigate the probability of metastases.
RESULTS: The data available in Asia (98%) and Latin America (100%) were hospital data, while in Europe, patients were treated both in hospitals and in office-based practices (62%, 38%). The mean age in Asia and Latin America (57 ± 13) was lower than in Europe (61 ± 13; p < 0.001). Lobular BC was diagnosed twice as often in Europe compared to Asia and Latin America (15.2%, 9.8%, 8.0%). The number of patients with metastasized hormone receptor-positive (HR +) BC was significantly higher in Europe and Latin America than in Asia (76%, 68%; p < 0.001). The highest number of women with metastasized BC was reported in Europe (26% compared to 14% and 20%, respectively, in Asia and Latin America). Across the continents, the percentage of women with BC who experienced metastases was 51-61% for bone, 30-39% for lung and 25-32% for liver, followed by 3-6% for skin and 3% for brain.
CONCLUSIONS: Women with BC treated in Europe tend to be significantly older and more likely to develop metastases than women in Asia and Latin America, except for lung metastases.
摘要：
目的：本研究的目的是在洲际比较中评估接受治疗的乳腺癌（BC）女性的基线数据。
方法：这项研究包括来自欧洲的99,571名女性BC（70,834），亚洲（18,208），和拉丁美洲（10,529）在2017年至2021年之间注册，基于IQVIA肿瘤学动态数据库的数据。该来源通过横断面部分回顾性调查提供信息，该调查收集了由肿瘤学家代表小组治疗的住院患者和门诊患者的匿名数据。使用多变量逻辑回归模型来研究转移的可能性。
结果：亚洲（98％）和拉丁美洲（100％）的可用数据是医院数据，而在欧洲,患者在医院和办公室诊所接受治疗(62%，38%)。亚洲和拉丁美洲的平均年龄（57±13）低于欧洲（61±13；p<0.001）。与亚洲和拉丁美洲相比，欧洲的小叶BC被诊断为两倍（15.2％，9.8%,8.0%）。欧洲和拉丁美洲的转移性激素受体阳性（HR）BC患者人数明显高于亚洲（76％，68%；p<0.001)。据报道，女性转移BC的人数最多（26％，而14％和20％，分别,在亚洲和拉丁美洲)。在各大洲，女性BC发生骨转移的比例为51-61%，30-39%的肺和25-32%的肝脏，其次是3-6％的皮肤和3％的大脑。
结论：与亚洲和拉丁美洲的女性相比，在欧洲接受治疗的女性往往年龄更大，并且更容易发生转移。除了肺转移.
方法：这项研究包括来自欧洲的99,571名女性BC（70,834），亚洲（18,208），和拉丁美洲（10,529）在2017年至2021年之间注册，基于IQVIA肿瘤学动态数据库的数据。该来源通过横断面部分回顾性调查提供信息，该调查收集了由肿瘤学家代表小组治疗的住院患者和门诊患者的匿名数据。使用多变量逻辑回归模型来研究转移的可能性。
结果：亚洲（98％）和拉丁美洲（100％）的可用数据是医院数据，而在欧洲,患者在医院和办公室诊所接受治疗(62%，38%)。亚洲和拉丁美洲的平均年龄（57±13）低于欧洲（61±13；p<0.001）。与亚洲和拉丁美洲相比，欧洲的小叶BC被诊断为两倍（15.2％，9.8%,8.0%）。欧洲和拉丁美洲的转移性激素受体阳性（HR）BC患者人数明显高于亚洲（76％，68%；p<0.001)。据报道，女性转移BC的人数最多（26％，而14％和20％，分别,在亚洲和拉丁美洲)。在各大洲，女性BC发生骨转移的比例为51-61%，30-39%的肺和25-32%的肝脏，其次是3-6％的皮肤和3％的大脑。
结论：与亚洲和拉丁美洲的女性相比，在欧洲接受治疗的女性往往年龄更大，并且更容易发生转移。除了肺转移.
